Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;15(1):e20-e27.
doi: 10.1183/20734735.0362-2018.

Over- and under-diagnosis in asthma

Affiliations
Review

Over- and under-diagnosis in asthma

Joanne Kavanagh et al. Breathe (Sheff). 2019 Mar.

Abstract

Asthma is extremely common with a prevalence of approximately 10% in Europe. It presents with symptoms which have a broad differential diagnosis and examination can be entirely normal. There is no agreed gold standard to diagnose asthma, and the objective tests that can aid diagnosis are often poorly available to primary care physicians. There is evidence that asthma is widely misdiagnosed. Overdiagnosis leads to unnecessary treatment and a delay in making an alternative diagnosis. Underdiagnosis risks daily symptoms, (potentially serious) exacerbations and long-term airway remodelling. An agreed standardised approach to diagnosis, with inclusion of objective measurements prior to treatment, is required to reduce misdiagnosis of asthma.

Key points: Asthma presents with common respiratory symptoms and physical examination is often normal; in addition, the most widely available tests (peak flow and spirometry) can be normal unless the patient is exacerbating.Treating asthma prior to carrying out objective tests decreases their sensitivity and can make confirmation of the diagnosis difficult.There is no single gold standard test to diagnose asthma, and there are significant differences between the suggested algorithms in commonly used guidelines.Both under- and over-diagnosis are widespread and lead to significant risks to patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J. Kavanagh has nothing to disclose. Conflict of interest: D.J. Jackson reports personal fees from Astra-Zeneca, Napp Pharmaceuticals, Chiesi Pharmaceuticals, and GSK, and non-financial support from Boehringer-Ingelheim and Teva Pharmacueticals, outside the submitted work. Conflict of interest: B.D. Kent reports personal fees from Astra-Zeneca, Napp Pharmaceuticals, and Chiesi Pharmaceuticals, and non-financial support from Boehringer-Ingelheim and Teva Pharmacueticals, outside the submitted work.

Similar articles

Cited by

References

    1. Gibson GJ, Loddenkemper R, Lundbäck B, et al., eds. The European Lung White Book: Respiratory Health and Disease in Europe. Sheffield, European Respiratory Society, 2013. - PubMed
    1. Asthma UK Asthma facts and statistics. www.asthma.org.uk/about/media/facts-and-statistics/ Date last accessed: 2018.
    1. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ 2012; 344: e3502. - PubMed
    1. Global Initiative for Asthma Global Strategy for Asthma Management and Prevention. 2018. https://ginasthma.org/
    1. British Thoracic Society, Scottish Intercollegiate Guidelines Network British guideline on the management of asthma: A national clinical guideline. 2016. www.sign.ac.uk/assets/sign153.pdf

LinkOut - more resources